Wedbush Brokers Raise Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Investment analysts at Wedbush lifted their Q1 2025 EPS estimates for Arvinas in a research note issued on Wednesday, March 12th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.76) per share for the quarter, up from their previous forecast of ($0.93). Wedbush currently has a "Neutral" rating and a $12.00 target price on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. Wedbush also issued estimates for Arvinas' Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.95) EPS, FY2028 earnings at ($3.63) EPS and FY2029 earnings at ($3.43) EPS.

A number of other equities analysts have also weighed in on the stock. Citigroup dropped their price target on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research report on Friday, March 7th. Oppenheimer cut shares of Arvinas from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $81.00 target price on shares of Arvinas in a research report on Tuesday, March 11th. BTIG Research began coverage on shares of Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 price objective for the company. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Five investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $37.47.

Remove Ads

Arvinas Stock Down 2.9 %

Shares of Arvinas stock traded down $0.27 during trading hours on Monday, reaching $8.74. 1,756,145 shares of the stock traded hands, compared to its average volume of 931,733. The company has a 50 day moving average price of $16.44 and a 200 day moving average price of $21.41. Arvinas has a one year low of $7.91 and a one year high of $44.85. The firm has a market capitalization of $600.72 million, a price-to-earnings ratio of -3.17 and a beta of 1.95.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company posted ($2.53) EPS.

Insider Transactions at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ian Taylor sold 9,020 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now owns 159,121 shares in the company, valued at approximately $2,658,911.91. This represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock worth $769,402 over the last 90 days. 5.23% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arvinas

A number of institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC acquired a new stake in shares of Arvinas in the third quarter valued at about $350,000. Algert Global LLC lifted its holdings in Arvinas by 278.1% in the 3rd quarter. Algert Global LLC now owns 168,061 shares of the company's stock valued at $4,139,000 after purchasing an additional 123,613 shares in the last quarter. FMR LLC grew its holdings in shares of Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock worth $71,023,000 after buying an additional 204,317 shares in the last quarter. Quantbot Technologies LP lifted its stake in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Finally, PEAK6 Investments LLC raised its holdings in Arvinas by 42.9% in the 3rd quarter. PEAK6 Investments LLC now owns 15,000 shares of the company's stock valued at $369,000 after acquiring an additional 4,500 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.